Shuttle Pharmaceuticals Holdings, Inc. — Q3 2022 Form 10-Q Summary
Business context and reporting period
The filing covers the unaudited quarter and nine months ended September 30, 2022. Shuttle is a development-stage pharmaceutical company focused on cancer-radiation sensitizers, normal-tissue protectants, HDAC inhibitors and related immunotherapy applications. Key programs include Ropidoxuridine, SP-2-225, predictive radiation-response biomarkers and prostate cancer research.
The company completed its initial public offering in September 2022 and had 13,586,393 common shares outstanding as of November 14, 2022. A 2-for-1 reverse stock split became effective April 1, 2022.
Financial performance and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 in 2022 and 2021 | $0 in 2022 and 2021 |
| Operating expenses | $821,468, compared with $242,116 | $1,813,490, compared with $754,453 |
| Net loss | $998,425, compared with $216,961 | $2,277,539, compared with $693,086 |
| Net loss attributable to common stockholders | $1,017,898, or $0.10 per share | $2,348,548, or $0.23 per share |
| Operating cash flow | Not separately reported for the quarter | $(2,030,587), compared with $(165,185) |
| Cash balance | $9,120,390 at September 30, 2022, compared with $504,749 at December 31, 2021 |
Q3 research and development expense, net of contract reimbursements, increased 258% to $669,038, primarily because of a $450,000 initial milestone payment to TCG GreenChem for IPdR process development and cGMP manufacturing. Nine-month net R&D expense increased 81% to $1,048,821. Nine-month NIH reimbursements declined to $211,455 from $422,910.
Legal and professional expense increased 326% for the nine-month period to $659,958, mainly due to pre-IPO financing and IPO preparation. Interest expense increased to $920,660 for the nine months, substantially reflecting amortization of debt discounts.
Working capital was $8,319,016 at September 30, 2022, versus a working-capital deficit of $1,707,716 at December 31, 2021. Financing activities provided $10,646,228, including $10,045,513 from common-stock issuance and warrant exercises. No investing cash flow was reported.
At September 30, 2022, total liabilities were $977,141, including $685,473 of related-party notes payable and $91,904 of accrued interest payable, including related-party interest. The company reported no conventional notes payable, PPP debt or derivative liability at period-end. Related-party notes were extended to June 30, 2023.
Material changes versus the prior comparable period
- Revenue remained zero, and the company continued to operate without positive operating cash flow.
- Q3 net loss increased by $781,464, or 360%, and nine-month net loss increased by $1,584,453, or 229%.
- R&D spending increased substantially as NIH-funded work ended and company-funded development expanded, including the TCG GreenChem manufacturing program.
- Financing and IPO-related activity increased cash from $504,749 at year-end 2021 to $9,120,390 at September 30, 2022.
- Series A preferred stock was converted into common stock and warrants; all 1,213 preferred shares were outstanding at December 31, 2021 but none remained at September 30, 2022.
- Most previously issued warrants were exercised. The filing reports 20,000 common-stock warrants outstanding at September 30, 2022, exercisable at $2.50 per share.
- Accounts payable and accrued expenses declined from $828,313 to $107,153, while dividends payable declined from $331,059 to zero after settlement through common stock.
Guidance, outlook, risks and unusual items
The filing provides no quantitative revenue, earnings or cash-flow guidance. Management expects to continue spending substantially on clinical development, regulatory preparation, preclinical and clinical studies, manufacturing, potential commercialization and future product candidates.
- The company has no approved commercial products and has generated no revenue. Product candidates require successful preclinical and clinical testing and FDA approval, with no assurance of timely approval or commercialization.
- Management states that additional financing may be required. Financing may be unavailable or dilutive, and insufficient funding could delay or curtail the business plan.
- NIH SBIR contracts and related research projects provided important historical funding, but the principal reported projects were completed and the company is increasingly funding R&D itself.
- The company entered a $1.5 million TCG GreenChem manufacturing and process-development project with four milestone payments; $450,000 was paid during Q3 2022.
- Unusual Q3 and nine-month items included a $328,687 gain on settlement of accounts payable, a $73,007 PPP-loan forgiveness gain for the nine-month period, a $94,025 warrant-liability fair-value gain and significant non-cash debt-discount amortization.
- Management identified material weaknesses in internal controls, including insufficient accounting personnel, inadequate written procedures and weaknesses in the financial-statement closing process. Remediation efforts include additional accountants and consultants and revised controls.
- The filing states that no legal proceedings were pending or threatened, no separate risk-factor updates were reported, and no material subsequent events required disclosure through November 14, 2022.
Important facts for investors to verify
- Cash runway relative to the company’s recurring operating losses, projected R&D commitments and the remaining TCG GreenChem milestone payments.
- Terms, maturity extensions, interest rates and potential dilution associated with the $685,473 of related-party notes and the remaining warrants.
- Progress, costs and deliverables under the $1.5 million TCG GreenChem manufacturing agreement.
- Clinical, regulatory and financing milestones for Ropidoxuridine, SP-2-225 and other product candidates.
- Remediation and auditor implications of the reported material weaknesses in internal controls.
- The MD&A contains an apparent inconsistency: one cash-flow discussion refers to a nine-month net loss of $2,258,635, while the consolidated financial statements report $2,277,539. The financial statements and final filed XBRL data should be verified.